Skip to main content

Advertisement

SpringerLink
Log in

New insights into the pathophysiology of irritable bowel syndrome: Implications for future treatments

  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Irritable bowel syndrome (IBS) is a multifactorial disorder characterized by abdominal pain and altered bowel habits. Chronic symptoms may occur due to changes in gastrointestinal motor function, enhanced perception of gut stimuli, and psychosocial factors. Recent data suggest that abnormal processing of afferent signals occurs in IBS patients. A newly recognized causative factor in a subset of IBS patients is postinfectious IBS. Altered transport of intestinal gas and bowel distention may contribute to abdominal discomfort, pain, and bloating. Changes in gut microflora have also been reported, but data remain scant. Advances have been made in our understanding of serotonin signaling and metabolism in IBS patients, in part due to the introduction of specific receptor agonists and antagonists. Finally, exciting data are emerging on genetic alterations that may contribute to the pathophysiology and treatment of IBS. Increasingly novel mechanisms are being identified that should aid in better understanding of the complex pathophysiology of IBS and developing new therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Mertz H, Naliboff B, Munakata J, et al.: Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995, 109:40–52.

    Article  PubMed  CAS  Google Scholar 

  2. Delvaux M: Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome. Gut 2002, 51(Suppl 1):i67-i71.

    Article  PubMed  Google Scholar 

  3. Whitehead WE, Palsson OS: Is rectal pain sensitivity a biological marker for irritable bowel syndrome: psychological influences on pain perception. Gastroenterology 1998, 115:1263–71.

    Article  PubMed  CAS  Google Scholar 

  4. Drossman DA: Review article: an integrated approach to the irritable bowel syndrome. Aliment Pharmacol Ther 1999, 13(Suppl 2):3–14.

    Article  PubMed  Google Scholar 

  5. Camilleri M, Talley NJ: Pathophysiology as a basis for understanding symptom complexes and therapeutic targets. Neurogastroenterol Motil 2004, 16:135–142. The authors provide a very important evaluation of the use of biomarkers for the evaluation of the potential therapeutic benefits of new pharmacologic interventions. Evaluation of pharmacodynamics can be performed in smaller patient samples and much more quickly than phase II clinical trials. Improved efficiency in identifying potential new therapeutic compounds can greatly enhance the availability of new treatments for patients with disorders of gastrointestinal function.

    Article  PubMed  CAS  Google Scholar 

  6. Viramontes BE, Camilleri M, McKinzie S, et al.: Gender related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001, 92:2671–2676.

    Article  Google Scholar 

  7. Prather CM, Camilleri M, Zinsmeister AR, et al.: Tegaserod accelerates orocecal transit in patients with constipationpredominant irritable bowel syndrome. Gastroenterology 2000, 96:455–459.

    Google Scholar 

  8. Cremonini F, Delgado-Aros S, Camilleri M: Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized control trials. Neurogastroenterol Motil 2003, 15:79–86.

    Article  PubMed  CAS  Google Scholar 

  9. Novick J, Miner P, Krause R, et al.: A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome. Aliment Pharmacol Ther 2002, 16:1877–1888.

    Article  PubMed  CAS  Google Scholar 

  10. Kellow J, Lee OY, Chang FY, et al.: An Asia-Pacific, double blind, placebo controlled, randomized study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003, 52:671–676.

    Article  PubMed  CAS  Google Scholar 

  11. Mertz H: Psychotherapeutics and serotonin agonists and antagonists. J Clin Gastroenterol 2005, 39:S247-S250.

    Article  PubMed  Google Scholar 

  12. Camilleri M, McKinzie S, Fox J, Foxx-Orenstein A, et al.: Effect of renzapride on transit in constipation-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2004, 2:895–904.

    Article  PubMed  CAS  Google Scholar 

  13. Coulie B, Camilleri M, Gupta V, et al.: Evidence for autonomic dysregulation in the irritable bowel syndrome. Dig Dis Sci 2002, 47:1716–1722.

    Article  Google Scholar 

  14. Bouin M, Plourde V, Boivin M, et al.: Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology 2002, 122:1771–1777.

    Article  PubMed  Google Scholar 

  15. Riberdy-Poitras M, Verrier P, Plourde V, et al.: Amitriptyline for the treatment of IBS [abstract]. Gastroenterology 2000, 118:A617.

    Article  Google Scholar 

  16. Delgado-Aros S, Chial HJ, Camilleri M, et al.: Effects of a Kappa opioid agonist, asimadoline, on satiation and gastrointestinal motor and sensory functions in humans. Am J Physiol 200, 284:G558-G566.

    Google Scholar 

  17. Cook IJ, Van Eden A, Collins SM: Patients with irritable bowel syndrome have greater pain tolerance than normal subjects. Gastroenterology 1987, 93:727–733.

    PubMed  CAS  Google Scholar 

  18. Chang L, Mayer EA, FitzGerald L, et al.: Differences in somatic perception in patients with irritable bowel syndrome with and without fibromyalgia. Pain 2000, 84:297–307.

    Article  PubMed  CAS  Google Scholar 

  19. Verne GN, Robinson ME, Vase L, Price DD: Reversal of visceral and cutaneous hyperalgesia by local rectal anesthesia in irritable bowel syndrome (IBS) patients. Pain 2003, 105:223–230.

    Article  PubMed  Google Scholar 

  20. Kwan CL, Diamant NE, Mikula K, Davis KD: Characteristics of rectal perception are altered in irritable bowel syndrome. Pain 2005, 113:160–71.

    Article  PubMed  Google Scholar 

  21. Bouin M, Lupien F, Riberdy M, et al.: Intolerance to visceral distension in functional dyspepsia or irritable bowel syndrome: an organ specific defect or a pan intestinal dysregulation? Neurogastroenterol Motil 2004, 16:311–314.

    Article  PubMed  CAS  Google Scholar 

  22. Holtmann G, Goebell H, Talley NJ: Functional dyspepsia and irritable bowel syndrome: Is there a common pathophysiological basis? Am J Gastroenterol 1997, 92:954–959.

    PubMed  CAS  Google Scholar 

  23. Talley NJ, Dennis EH, Schettler-Duncan VA, et al.: Overlapping upper and lower gastrointestinal symptoms in irritable bowel syndrome with patients with constipation or diarrhea. Am J Gastroenterol 2003, 98:2454–2459.

    Article  PubMed  Google Scholar 

  24. Kilkens TO, Honig A, van Nieuwenhoven MA, et al.: Acute tryptophan depletion affects brain-gut responses in irritable bowel syndrome patients and controls. Gut 2004, 53:1794–1800.

    Article  PubMed  CAS  Google Scholar 

  25. Naliboff BD, Munakata J, Fullerton S, et al.: Evidence for two distinct perceptual alterations in irritable bowel syndrome. Gut 1997, 41:505–512.

    Article  PubMed  CAS  Google Scholar 

  26. Mertz H, Morgan V, Tanner G, et al.: Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. Gastroenterology 2000, 118:842–848.

    Article  PubMed  CAS  Google Scholar 

  27. Naliboff BD, Derbyshire SW, Munakata J, et al.: Cerebral activation in patients with irritable bowel syndrome and control subjects during rectosigmoid stimulation. Psychosom Med 2001, 63:365–375.

    PubMed  CAS  Google Scholar 

  28. Sidhu H, Kern M, Shaker R: Absence of increasing cortical fMRI activity volume in response to increasing visceral stimulation in IBS patients. Am J Physiol Gastrointest Liver Physiol 2004, 287:G425-G435.

    Article  PubMed  CAS  Google Scholar 

  29. Dickhaus B, Mayer EA, Firooz N, et al.: Effect of auditory stress on perceptual and emotional ratings of visceral stimuli in IBS patients. Am J Gastroenterol 2003, 98:135–143.

    Article  PubMed  Google Scholar 

  30. Sagami Y, Shimada Y, Tayama J, et al.: Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut 2004, 53:958–964.

    Article  PubMed  CAS  Google Scholar 

  31. Posserud I, Agerforz P, Ekman R, et al.: Altered visceral perceptual and neuroendocrine response in patients with irritable bowel syndrome during mental stress. Gut 2004, 53:1102–1108.

    Article  PubMed  CAS  Google Scholar 

  32. Lee OY, Mayer EA, Schmulson M, et al.: Gender-related differences in IBS symptoms. Am J Gastroenterol 2001, 96:2184–2193.

    Article  PubMed  CAS  Google Scholar 

  33. Mayer EA, Berman S, Chang L, Naliboff BD: Sex-based differences in gastrointestinal pain. Eur J Pain 2004, 8(5):451–463.

    Article  PubMed  Google Scholar 

  34. Waring WS, Chui M, Japp A, et al.: Autonomic cardiovascular responses are impaired in women with irritable bowel syndrome. J Clin Gastroenterol 2004, 38:658–663.

    Article  PubMed  Google Scholar 

  35. Naliboff BD, Berman S, Chang L, et al.: Sex-related differences in IBS patients: central processing of visceral stimuli. Gastroenterology 2003, 124:1738–1747.

    Article  PubMed  Google Scholar 

  36. Rollman GB, Abdel-Shaheed J, Gillespie JM, Jones KS: Does past pain influence current pain: biological and psychosocial models of sex differences. Eur J Pain 2004, 8:427–433.

    Article  PubMed  Google Scholar 

  37. Sarlani E, Grace EG, Reynolds MA, Greenspan JD: Sex differences in temporal summation of pain and aftersensations following repetitive noxious mechanical stimulation. Pain 2004, 109:115–23.

    Article  PubMed  Google Scholar 

  38. Spiller RC: Inflammation as a basis for functional GI disorders. Best Pract Res Clin Gastroenterol 2004, 14:641–661. Excellent review of the proposed mechanism of post-infectious functional disorders, IBS, and gastroparesis with clinical management guidelines.

    Article  CAS  Google Scholar 

  39. Neal KR, Hebden J, Spiller R: Prelance of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for the development of irritable bowel syndrome; postal survey of patients. BMJ 1997, 7083:779–782.

    Google Scholar 

  40. Okhuysen PC, Jiang ZD, Carlin L, et al.: Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am J Gastroent 2004, 99:1774–1778.

    Article  PubMed  Google Scholar 

  41. Wang LH, Fang XC, Pan GZ: Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut 2004, 53:1096–1101.

    Article  PubMed  CAS  Google Scholar 

  42. Barbara G, Stanghellini V, De Giorgio R, et al.: Activated mast cells in proximity to colonic nerves correlates with abdominal pain in irritable bowel syndrome. Gastroenterology 2004, 126:693–672.

    Article  PubMed  Google Scholar 

  43. Simren M, Axelsson J, Gillberg R, et al.: Quality of life in inflammatory bowel disease in transmission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol 2002, 97:389–396.

    PubMed  Google Scholar 

  44. Spiller RC: Postinfectious irritable bowel syndrome. Gastroenterology 2003, 124:1662–1671.

    Article  PubMed  Google Scholar 

  45. Bernstein CN, Niazi N, Robert M, et al.: Rectal afferent function in patients with inflammatory and functional intestinal disorders. Pain 1996, 66:151–161.

    Article  PubMed  CAS  Google Scholar 

  46. Chang L, Munakata J, Mayer EA, et al.: Perceptual responses in patients with inflammatory and functional bowel disease. Gut 2000, 47:497–505.

    Article  PubMed  CAS  Google Scholar 

  47. Swidsinki A, Khilkin M, Ortner M, et al.: Alteration of bacterial concentrations in colonic biopsies from patients with irritable bowel syndrome (IBS) [abstract]. Gastroenterology 1999, 116:A1.

    Article  Google Scholar 

  48. O’Mahony L, McCarthy J, Kelly P, et al.: Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005, 128:541–551. One of the first studies to demonstrate symptomatic response associated with normalization of anti-inflammatory to proinflammatory cytokines in IBS patients. Their results suggest an immune-modulating role for probiotics.

    Article  PubMed  Google Scholar 

  49. Kim HJ, Camilleri M, McKinzie S, et al.: A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003, 17:895–904.

    Article  PubMed  CAS  Google Scholar 

  50. Saggioro A: Probiotics in the treatment of irritable bowel syndrome. J Clin Gastroenterol 2004, 38(Suppl 6):S104-S106.

    Article  PubMed  Google Scholar 

  51. Lin H: Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 2004, 292:852–857.

    Article  PubMed  CAS  Google Scholar 

  52. Pimental M, Chow EJ, Lin HC: Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000, 95:3503–3506.

    Article  Google Scholar 

  53. Di Stefano M, Miceli E, Armellini E, et al.: Probiotics and functional abdominal bloating. J Clin Gastroenterol 2004, 38(Suppl):S102-S103.

    Article  Google Scholar 

  54. Di Stefano M, Strocchi A, Malservisi S, et al.: Non-absorbable antibiotics for managing intestinal gas production and gasrelated symptoms. Aliment Pharmacol Ther 2000, 14:1001–1008.

    Article  Google Scholar 

  55. Lewis MJ, Reilly B, Houghton LA, Whorwell PJ: Ambulatory abdominal inductance plethysmography: towards objective assessment of abdominal distension in irritable bowel syndrome. Gut 2001, 48:216–220.

    Article  PubMed  CAS  Google Scholar 

  56. Maxton DG, Martin DF, Whorwell PJ, Godfrey M: Abdominal distension in female patients with irritable bowel syndrome: exploration of possible mechanisms. Gut 1991, 32:662–664.

    PubMed  CAS  Google Scholar 

  57. Koide A, Yamaguchi T, Odaka T, et al.: Quantitative analysis of bowel gas using plain abdominal radiograph in patients with irritable bowel syndrome. Am J Gastroenterol 2000, 95:1735–1741.

    Article  PubMed  CAS  Google Scholar 

  58. Chami TN, Schuster MM, Bohlman ME, et al.: A simple radiologic method to estimate the quantity of bowel gas. Am J Gastroenterol 1991, 86:599–602.

    PubMed  CAS  Google Scholar 

  59. Serra J, Azpiroz F, Malagelada JR: Mechanisms of intestinal gas retention in humans: impaired propulsion versus obstructed evacuation. Am J Physiol Gastrointest Liver Physiol 2001, 281:G138-G143.

    PubMed  CAS  Google Scholar 

  60. Azpiroz F, Enck P, Whitehead WE: Anorectal functional testing: review of collective experience. Am J Gastroenterol 2002, 97:232–240.

    PubMed  Google Scholar 

  61. Serra J, Azpiroz F, Malagelada JR: Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome. Gut 2001, 48:14–19.

    Article  PubMed  CAS  Google Scholar 

  62. Hernando-Harder AC, Serra J, Azpiroz F, Malagelada JR: Sites of symptomatic gas retention during intestinal lipid perfusion in healthy subjects. Gut 2004, 53:661–665.

    Article  PubMed  CAS  Google Scholar 

  63. Lin HC, Chen JH: Slowing of intestinal transit by fat depends on an ondansetron-sensitive, efferent serotonergic pathway. Neurogastroenterol Motil 2003, 15:317–322.

    Article  PubMed  CAS  Google Scholar 

  64. Evans PR, Kellow JE: Physiological modulation of jejunal sensitivity in health and in irritable bowel syndrome. Am J Gastroenterol 1998, 93:2191–2196.

    Article  PubMed  CAS  Google Scholar 

  65. Kellow JE, Eckersley CM, Jones MP: Enhanced perception of physiological intestinal motility in the irritable bowel syndrome. Gastroenterology 1991, 101:1621–1627.

    PubMed  CAS  Google Scholar 

  66. Galati JS, McKee DP, Quigley EM: Response to intraluminal gas in irritable bowel syndrome: motility versus perception. Dig Dis Sci 1995, 40:1381–1387.

    Article  PubMed  CAS  Google Scholar 

  67. Locke GR III, Zinsmeister AR, Talley NJ, et al.: Familial association in adults with functional gastrointestinal disorders. Mayo Clinic Proc 2000, 75:907–912.

    Article  Google Scholar 

  68. Levy RL, Jones KR, Whitehead WE, et al.: Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology 2001, 121:799–804.

    Article  PubMed  CAS  Google Scholar 

  69. Gonsalkorale WM, Perrey C, Pravica V, et al.: Interleukin-10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut 2003, 52:91–93.

    Article  PubMed  CAS  Google Scholar 

  70. Camilleri M, Atanasova E, Carlson PJ, et al.: Serotonintransporter polymorphism pharmacogenetics in diarrheapredominant irritable bowel syndrome. Gastroenterology 2002, 123:425–432.

    Article  PubMed  CAS  Google Scholar 

  71. Pata C, Erdal ME, Derci E, et al.: Serotonin transporter gene polymorphisms in irritable bowel syndrome. Am J Gastroenterol 2002, 97:1780–1784.

    Article  PubMed  CAS  Google Scholar 

  72. Yeo A, Boyd P, Lumsden S, et al.: Association between a functional polymorphism in the serotonin transporter gene and diarrhea predominant irritable bowel syndrome in women. Gut 2004, 53:1452–1458.

    Article  PubMed  CAS  Google Scholar 

  73. Kim HJ, Camilleri M, Carlson PJ, et al.: Association of distinct alpha2A adrenoreceptor and serotonin-transporter polymorphisms associated with constipation and somatic symptoms in functional gastrointestinal disorders. Gut 2004, 53:829–837.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Mayo Clinic Scottsdale, 13400 E. Shea Boulevard, 85259, Scottsdale, AZ, USA

    Michael D. Crowell PhD

Authors
  1. Michael D. Crowell PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lucinda Harris MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael P. Jones MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lin Chang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Crowell, M.D., Harris, L., Jones, M.P. et al. New insights into the pathophysiology of irritable bowel syndrome: Implications for future treatments. Curr Gastroenterol Rep 7, 272–279 (2005). https://doi.org/10.1007/s11894-005-0019-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-005-0019-8

Keywords

Search

Navigation